• May 4, 2024

In Mexico, heart attacks they appear in the most productive stage of people (35 and 50 years of age).

Data from National Health Information System (SINAIS) of the Federal Health Secretariat notes that since 2008, ischemic heart disease occupies the second place of mortality, and of these 50% belong to the Acute Coronary Ischemic Syndrome (SICA).

According to the doctor Javier Antezana , cardiologist of the Coronary Unit of the UMAE Hospital of Cardiology National Medical Center Siglo XXI , deaths from heart disease accounted for 17.2% of the total deaths among men and women.

New Hope...

In this regard, it was announced at a press conference that Mexico is the first country in Latin America and the second in the world to obtain the approval of Xarelto (Rivaroxaban), as the first oral anticoagulant for the secondary prevention of a myocardial infarction in addition to the traditional antiplatelet dual therapy (aspirin and thienopyridine).

In this sense, the medical Alejandra Meaney, cardiologist of the Medical Management of Bayer HealthCare Pharmaceuticals , he pointed:

"The new treatment is to offer patients who had a first myocardial infarction the triple therapy (conformed by the traditional dual antiplatelet therapy plus Rivaroxaban) to avoid the occurrence of another cardiovascular event in the following year, managing to reduce the risk up to 8.9% ".

This is the first innovation in the treatment of SICA, after several decades in which an alternative was sought to reduce a second heart attack. With its approval, Mexico is at the forefront in terms of prevention of cardiovascular health, the specialists commented.

It should be noted that this drug does not interfere with the intake of any food as in the past, which had to maintain strict food control.